Celsion Corporation (Celsion) has received approval from China’s State Food and Drug Administration (SFDA) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical
In January 2009, Tyrian reported that its lead TB marker was detected in clinical strains of the bacteria responsible for TB as well as in clinical sputum samples;
Health Decisions has built international CRO community on the company’s Agile Clinical Development methodology, to raise the standard of efficiency in global trials. The company has said that
Threshold Pharmaceuticals and Eleison Pharmaceuticals have executed a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide. Reportedly, Glufosfamide is a novel small molecule that has been
In their answer, Illumina and Solexa have denied all of Life Technologies’s and Applied Biosystems’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.
Pfizer has entered into a settlement and license agreement with Mylan Pharmaceuticals and Matrix Laboratories subsidiaries relating to Voriconazole Tablets, 50 mg and 200 mg, the generic version
Suven Life Sciences’ has said that its clinical candidate SUVN-502 for Alzheimer’s Disease secured several product patents granted at all the key market countries; India (218438), Mexico (257091),
Basilea Pharmaceutica (Basilea) has reported that Toctino (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been
Galapagos has expanded its global strategic alliance in metabolic diseases with Merck &, an affiliate of Merck & Co., to incorporate the development of new therapies for atherosclerosis.
Sosei Group (Sosei) has entered into a deal with Biocopea Limited (Biocopea), a subsidiary of PepTcell, for the drug discovery program, SD281 and its analogues. The company has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.